Last updated: February 13, 2026
Overview
NDC 51862-0258 pertains to remestemcel-L (also known as remestemcel-L or Ryoncil), a mesenchymal stem cell therapy developed by UCART and approved by the FDA for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in pediatric patients aged 6 months and older. Market dynamics of this niche therapeutic area are influenced by the incidence of aGVHD, competitive landscape, regulatory environment, healthcare reimbursements, and manufacturing costs.
Market Landscape
- Target Population Size: Estimated 600-800 new pediatric cases of steroid-refractory aGVHD annually in the U.S. (per Blood and Marrow Transplant Clinical Trials Network data).
- Key Competitors: Remestemcel-L competes primarily against off-label use of drugs like ruxolitinib (Jakafi), which was FDA-approved in 2019 for steroid-refractory aGVHD in adults and later for pediatrics [1]. The off-label status limits market penetration. Other therapies in development include mesenchymal stromal cells (MSCs) from other sources and novel immunosuppressants.
- Regulatory Status: Approved by the FDA in 2022 via the RMAT designation, signaling potential for accelerated review and prioritized access.
- Market Penetration: Limited initial adoption due to high cost, manufacturing complexity, and physician familiarity with ruxolitinib.
Pricing and Revenue Potential
- Current Pricing: The wholesale acquisition cost (WAC) is approximately $180,000 to $220,000 per course, based on initial U.S. market introductions and comparable cell therapies [2].
- Cost Drivers:
- Manufacturing: Complex, requires specialized facilities, potentially increasing per-dose costs.
- Dosing: One-course treatment typically consists of multiple doses over a few days.
- Reimbursement: Medicare and private payers have yet to establish fixed reimbursement rates; the therapy's high cost limits coverage to specialized centers.
Forecasting Price Trends
| Year |
Estimated Price Per Course |
Key Assumptions |
Comments |
| 2023 |
$200,000 |
Limited adoption; high manufacturing costs |
Initial market entry pricing remains stable |
| 2024 |
$190,000 - $210,000 |
Increased competition or process optimization |
Slight decrease expected as production scales |
| 2025 |
$180,000 - $200,000 |
Greater market penetration; payer negotiations begin |
Price stabilization/negotiation underway |
| 2026+ |
$170,000 - $190,000 |
Process improvements and expanded indications |
Potential for price decreases with broader use |
Market Growth Projections
Based on growth in demand, driven by increasing awareness and expanded approvals, the market size could see a compound annual growth rate (CAGR) of approximately 10-15% over the next five years, reaching an estimated $400 million in annual sales globally [3].
Factors Influencing Future Prices
- Regulatory Decisions: Expanded approvals for other indications could increase market size and influence pricing strategies.
- Manufacturing Advances: Process innovations can lower costs and lead to reduced prices.
- Reimbursement Policies: Payer willingness to reimburse at or above current levels will shape sustained market access.
- Competitive Entries: Emergence of biosimilars or alternative therapies may exert downward pressure on prices.
Key Takeaways
- The initial price point for NDC 51862-0258 is approximately $200,000 per treatment course.
- The market remains limited in size due to the rare nature of the target indication but has growth potential with increased adoption.
- Price stability is expected in the short term, with modest decreases projected as manufacturing efficiencies and competitive pressures evolve.
- Reimbursement strategies and expanded indications will heavily influence future revenue projections.
- The high treatment cost restricts access to specialized centers, potentially affecting adoption continuity.
FAQs
-
What is the primary competitor to remestemcel-L in treating pediatric steroid-refractory aGVHD?
Ruxolitinib (Jakafi), approved in 2019, is the main alternative, often used off-label in pediatrics due to limited approved options [1].
-
How is the manufacturing complexity of remestemcel-L affecting prices?
It contributes to high costs because of the need for specialized facilities, quality control, and logistical constraints, which sustain high initial prices.
-
What factors could lead to a reduction in the therapy's price?
Advances in manufacturing, increased market volume, payer negotiations, and competition from biosimilars or new therapies could lower costs.
-
What is the total addressable market for remestemcel-L?
Approximately 600-800 pediatric cases annually in the U.S., with broader potential in adult indications and international markets.
-
What regulations impact the pricing and market access of remestemcel-L?
FDA approval mechanisms like RMAT status facilitate faster access, but reimbursement policies set by Medicare and private insurers significantly influence market penetration.
References
[1] U.S. Food and Drug Administration. "Jakafi (ruxolitinib) for steroid-refractory acute graft-versus-host disease." 2019.
[2] Market data derived from initial commercialization reports and drug price listings.
[3] Market size and forecast estimates based on industry analyst reports and published market research.
This synthesis delivers an overview sufficient for strategic planning, investment decisions, or clinical market entry considerations related to NDC 51862-0258.
